Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments

News, Press Releases

Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments STRO-002 Encouraging Interim Phase 1 Clinical Data from an Ongoing Dose Escalation Study in Ovarian Cancer Presented at the AACR Virtual Meeting STRO-001 Phase...

Sutro Biopharma Announces Proposed Public Offering

News, Press Releases

Sutro Biopharma Announces Proposed Public Offering South San Francisco, Calif., May 11, 2020 — Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free...

Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer

Events, News, Presentations, Press Releases

Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer –...

Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate

Events, News, Presentations, Press Releases

Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate -Company to present updated STRO-002 data at AACR Virtual Annual Meeting – SOUTH SAN FRANCISCO, Calif., April 20, 2020 – Sutro...

Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020

Events, News, Presentations, Press Releases

Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020 – Company to host a conference call following the presentation – SOUTH SAN FRANCISCO, Calif., April. 13, 2020 –...

SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia

News, Press Releases

SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia Foster City, CA, March 26, 2020 – SutroVax, a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to...
« Older Entries
Next Entries »

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080

Phone: 650-881-6500

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2026 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY  | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

 

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.